Adalimumab modulates angiogenesis in psoriatic skin

European Journal of Inflammation

Volumn 11, Issue 2, 2013, Pages 489-498

  Campanati, A ^a   Moroncini, G ^a   Ganzetti, Giulia ^a   Pozniak, K N ^a   Goteri, G ^a   Giuliano, A ^a   Martina, E ^a   Liberati, G ^a   Ricotti, F ^a   Gabrielli, A ^a   Offidani, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Adalimumab; Angiogenesis; Psoriasis

Indexed keywords

ADALIMUMAB; ANGIOPOIETIN 2; BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN; FOLLISTATIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR BB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLAROSCOPY; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIASIS; TREATMENT DURATION; TREATMENT RESPONSE; VIDEOENDOSCOPY;

EID: 84884315333     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1301100218     Document Type: Article

References (31)

1. Hern S, Mortimer PS. In vivo quantification of microvessels in clinically uninvolved psoriatic skin and in normal skin Br J Dermatol 2007; 156(6):1224-9. (Pubitemid 47029826)
2. Hern S, Stanton AW, Mellor RH, Harland CC, Levick JR, Mortimer PS. In vivo quantification of the structural abnormalities in psoriatic microvessels before and after pulsed dye laser treatment. Br J Dermatol 2005; 152(3):505-11. (Pubitemid 40547124)
3. Calabrese LH. Molecular differences in anti-cytokine therapies. Clin Exp Rheumatol 2003; 21:241-8.
4. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003; 21:241-8.
5. Trevisan G, Magaton Rizzi G, Dal Canton M. Psoriatic microangiopathy modifications induced by PUVA and etretinate therapy. A nail-fold capillary microscopic study. Acta Derm Venereol Suppl (Stockh)1989; 146:53-6.
6. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009; 90(3):232-48.
7. Parent D, Bernard BA, Desbas C, et al. Spreading of psoriatic plaques: alteration of epidermal differentiation precedes capillary leakiness and anomalies in vascular morphology. J Invest Dermatol 1990; 95:333-40. (Pubitemid 20261868)
8. Butt C, Lim S, Greenwood C, Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord 2007; 8:1-7
9. Yalçin B, Tezel GG, Arda N, Erman M, Alli N. Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis. Anal Quant Cytol Histol 2007; 29(6):358-64 (Pubitemid 350304993)
10. Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF-alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004; 279:32633-42. (Pubitemid 39014721)
11. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:563-9. (Pubitemid 39278075)
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19(3):210-6. (Pubitemid 24194579)
13. Farhi D, Falissard B, Dupuy A. Global assessment of psoriasis severity and change from photographs: a valid and consistent method. J Invest Dermatol 2008; 128:2198-203.
14. Campanati A, Goteri G, Simonetti O, et al. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: video- capillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol 2009; 22(2):371-7.
15. Gutierrez M, De Angelis R, Bernardini ML, et al. Clinical, power Doppler sonography and histological assessment of the psoriatic plaque: short-term monitoring in patients treated with etanercept. Br J Dermatol 2011; 164(1):33-7
16. Campanati A, Goteri G, Simonetti O, et al. CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br J Dermatol 2007; 157(6):1155-60. (Pubitemid 350115680)
17. Simonetti O, Lucarini G, Campanati A, et al. VEGF, survivin and NOS overexpression in psoriatic skin: critical role of nitric oxide synthases. J Dermatol Sci 2009; 54(3):205-8.
18. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis. Int J Exp Path 2009; 90:232-48.
19. Krzystek-Korpacka M, Neubauer K, Matusiewicz M. Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease. Clin Biochem 2009; 42(16-17):1602-9.
20. Stapor PC, Azimi MS, Ahsan T, Murfee WL. An angiogenesis model for investigating multicellular interactions across intact microvascular networks. Am J Physiol Heart Circ Physiol 2013; 304(2):H235-45.
21. Gao X, Hu H, Zhu J, Xu Z. Identification and characterization of follistatin as a novel angiogenin-binding protein. FEBS Lett 2007; 581(28):5505-10. (Pubitemid 350101537)
22. Braverman IM, Sibley J. The response of psoriatic epidermis and microvessel to treatment with topical steroids and oral methotrexate. J Invest Dermatol 1985;85:584-86. (Pubitemid 16204238)
23. Van de Kerkof PCM, van Rennes H, de Grood R. Metabolic changes at the margin of the spreading psoriatic lesion. Br J Dermatol 1983; 108:647-52
24. Chen DM, Gordon K, Leonardi C, Menter MA. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. J Am Acad Dermatol 2004; 50(3, Part II): 1 and PS 491, P2.
25. Langley R, Leonardi C, Toth D, Chen D. Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2005; 52(S):203.
26. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to Adalimumab treatment in moderate to severe psoriasis patients: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 4:598-606. (Pubitemid 44436647)
27. Cañete JD, Pablos JL, Sanmartí R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004; 50(5):1636-41. (Pubitemid 38608086)
28. Cordiali-Fei P, Ardigò M, Mastroianni A, et al. Serum cytokines and bioumoral immunological characterization of psoriatic patients in long term etanercept treatment. Int J Immunopathol Pharmacol 2008; 21(3):643-9.
29. Cordiali-Fei P, Trento E, D'Agosto G, et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann NY Acad Sci 2007; 1110:578-89. (Pubitemid 350043048)
30. Monica Guma, Gary S. Firesteinc-Jun N-Terminal kinase in inflammation and rheumatic diseases. Open Rheumatol J 2012; 6(S):20-231.
31. Kanakaraj P, Puffer BA, Yao XT, et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012; 4(5):600-13.